These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 14765771

  • 21. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [Abstract] [Full Text] [Related]

  • 22. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
    Fitzgerald DA.
    Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
    [Abstract] [Full Text] [Related]

  • 23. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B, Steele S, Janes M, Pinelli J.
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [Abstract] [Full Text] [Related]

  • 24. [Respiratory syncytial virus prophylaxis among preterm infants--four seasons' experience].
    Klimek M, Kwinta P, Kruczek P, Pietrzyk JJ.
    Przegl Lek; 2009 Jul; 66(1-2):34-8. PubMed ID: 19485253
    [Abstract] [Full Text] [Related]

  • 25. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T, Valkonen H, Lehtonen L, Vainionpää R, Ruuskanen O.
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
    [Abstract] [Full Text] [Related]

  • 26. Acute bronchiolitis in infancy as risk factor for wheezing and reduced pulmonary function by seven years in Akershus County, Norway.
    Fjaerli HO, Farstad T, Rød G, Ufert GK, Gulbrandsen P, Nakstad B.
    BMC Pediatr; 2005 Aug 18; 5():31. PubMed ID: 16109158
    [Abstract] [Full Text] [Related]

  • 27. Prevention and treatment of respiratory syncytial virus infection in infants: an update.
    Venkatesh MP, Weisman LE.
    Expert Rev Vaccines; 2006 Apr 18; 5(2):261-8. PubMed ID: 16608425
    [Abstract] [Full Text] [Related]

  • 28. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.
    Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O.
    Pediatr Infect Dis J; 2007 Dec 18; 26(12):1089-93. PubMed ID: 18043443
    [Abstract] [Full Text] [Related]

  • 29. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
    Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S.
    Pediatr Pulmonol; 2008 Feb 18; 43(2):169-74. PubMed ID: 18085710
    [Abstract] [Full Text] [Related]

  • 30. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM, Ceneviva GD, Brummel GL, Graff GR, Javier MC.
    Clin Ther; 2004 Dec 18; 26(12):2130-7. PubMed ID: 15823776
    [Abstract] [Full Text] [Related]

  • 31. The diagnostic and therapeutic approach to acute bronchiolitis in hospitalized children in Israel: a nationwide survey.
    Offer I, Ashkenazi S, Livni G, Shalit I.
    Isr Med Assoc J; 2000 Feb 18; 2(2):108-10. PubMed ID: 10804929
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Special populations.
    Fauroux B.
    Paediatr Respir Rev; 2009 Jun 18; 10 Suppl 1():21-2. PubMed ID: 19651396
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Serum KL-6 levels as a biomarker of lung injury in respiratory syncytial virus bronchiolitis.
    Kawasaki Y, Aoyagi Y, Abe Y, Go H, Imamura T, Kaneko M, Ito M, Katayose M, Hashimoto K, Hosoya M.
    J Med Virol; 2009 Dec 18; 81(12):2104-8. PubMed ID: 19856476
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Lipopolysaccharide hyporesponsiveness as a risk factor for intensive care unit hospitalization in infants with respiratory syncitial virus bronchiolitis.
    Mandelberg A, Tal G, Naugolny L, Cesar K, Oron A, Houri S, Gilad E, Somekh E.
    Clin Exp Immunol; 2006 Apr 18; 144(1):48-52. PubMed ID: 16542364
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.